Head-To-Head Comparison: ProKidney (NASDAQ:PROK) versus ReNeuron Group (OTCMKTS:RNUGF)

ProKidney (NASDAQ:PROK) and ReNeuron Group (OTCMKTS:RNUGF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Volatility & Risk

ProKidney has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, ReNeuron Group has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ProKidney and ReNeuron Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1	1	3	0	2.40
ReNeuron Group	0	0	0	0	0.00

ProKidney presently has a consensus price target of $6.25, suggesting a potential upside of 124.82%. Given ProKidney’s stronger consensus rating and higher probable upside, equities research analysts plainly believe ProKidney is more favorable than ReNeuron Group.

Profitability

This table compares ProKidney and ReNeuron Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-17.11%
ReNeuron Group	N/A	N/A	N/A

Earnings and Valuation

This table compares ProKidney and ReNeuron Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$527,000.00	1,552.38	-$61.19 million	($0.57)	-4.88
ReNeuron Group	$640,000.00	N/A	-$6.52 million	N/A	N/A

ReNeuron Group has higher revenue and earnings than ProKidney.

Insider and Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ProKidney beats ReNeuron Group on 6 of the 9 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.